Vinay Prasad Details New Approach to COVID-19 Vaccine Approvals in Recent FDA Memos on September 02, 2025 Child COVID19 (disease) Evidence Prasad regulatory decisions risk-benefit analysis Spikevax United States Food and Drug Administration vaccine approval Vaccine Safety Vaccines Vinay +
Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile on August 27, 2025 Center for Biologics Evaluation and Research gene therapy Lower Profile Prasad research Return to (contextual qualifier) (qualifier value) Titles United States Food and Drug Administration Vinay +
Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy on July 30, 2025 CBER conservative criticism departure - ActRelationshipType Drug Approval gene therapy Muscular Dystrophy, Duchenne Prasad United States Food and Drug Administration Vinay +
Vinay Prasad's First Major Policy: Challenging Covid Vaccine 'Dogma' at FDA on May 21, 2025 Clinical Trials COVID19 (disease) Policy Prasad public health medicine (field) Recommendation Regulatory Framework United States Food and Drug Administration Vaccines Vinay +